About
Synova Life Sciences develops the Synova WAVE system to process autologous adipose (fat) tissue into high-viability adipocytes for regenerative and aesthetic procedures; the device is FDA 510(k) cleared and designed for rapid (3-minute) processing. The company focuses on improving cell viability and processing speed for clinical use of fat-derived cells.
Explore Synova Life Sciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.